Testing of host-directed therapeutics in combination with anti-biotic regimens for mycobacterium tuberculosis (MTB) in mice
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $3,000,000 to $7,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 611310 Colleges, Universities, and Professional Schools
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health forecasts a new requirement for testing host-directed therapies in combination with antibiotic regimens for Mycobacterium tuberculosis in mice, with an estimated solicitation release date of 2026-06-01 and an estimated award date of 2026-08-01. The study will measure how effectively the HRZE and BPaLM regimens reduce bacteria in the lungs and prevent relapse after treatment stops, using multiple treatment durations and a relapse phase, and treatment options with durations shorter than 6 months are a high priority. The forecast uses NAICS 611310 (Colleges, Universities, and Professional Schools) with no set-aside.
The estimated award value range is $3.0 million to $7.0 million. Points of contact are Patrick Finn, Contracting Officer (patrick.finn@nih.gov, +1 240-669-5401), and Brigitte Sanders, titled PROGRAM OFFICER TARGETED (brigitte.sanders@nih.gov, 240-627-3209), both at the National Institutes of Health.
Forecast text
This study is needed to clearly show how well standard TB treatments and newer drug combinations work in a controlled setting before moving further into development. By using a well-established mouse model that mimics human tuberculosis infection, researchers can measure how effectively the HRZE and BPaLM regimens reduce bacteria in the lungs and prevent the disease from coming back after treatment stops. Including multiple treatment durations and a relapse phase helps capture both short-term and long-term effects, which are critical for understanding real-world treatment outcomes. Testing additional host-directed therapies alongside these regimens also helps identify whether they can improve treatment success. Overall, this approach provides reliable, high-quality data to guide decisions about which therapies are most promising and worth advancing.
STATEMENT OF IMPACT:
The use of host-directed therapies in conjunction with the standard antibiotic regimens HRZE and BPaLM is expected to lead to new therapeutic options that improve tuberculosis treatment outcomes, including for people living with HIV. If this request is not approved, the translational development of these potential treatment regimens may be slowed or halted, thereby delaying the advancement of these promising therapeutic approaches for clinical use.
Mycobacterium tuberculosis infections are particularly relevant in crowded settings, such as cruise ships, where transmission risk is elevated. Effective treatment options with durations shorter than 6 months are therefore a high priority. Currently, individuals infected in the United States typically require treatment for a minimum of 4-6 months, which is often impractical because many patients lack sufficient vacation or medical leave time to complete therapy. Developing shorter-duration treatment options that are also effective in preventing transmission to family members and close contacts remains a critical public health priority.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast